WASHINGTON - Gilead Sciences said on Monday its antiviral drug remdesivir had mixed results in a late-stage study of people with moderate Covid-19, as patients given a five-day course of the treatment showed statistically significant improvement, while those given it for 10 days did not.
Remdesivir, which previously failed as a treatment for Ebola, is designed to disable the mechanism by which certain viruses, including the new coronavirus, make copies of themselves and potentially overwhelm their host's immune system. The results announced by Gilead on Monday are from a study designed to evaluate the safety and efficacy of five- and 10-day treatmenst with remdesivir in addition to standard of care for patients with moderate Covid-19, compared with standard care alone.
At Day 11, more patients in the five-day treatment group showed improvement in clinical status versus the standard of care group, Gilead said. The drugmaker said the odds of improvement with the 10-day treatment course of remdesivir versus standard of care were also favourable, trending towards but not reaching statistical significance.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: The Straits Times - 🏆 8. / 63 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »